Cephalon’s ability to be first-to-market with innovative compounds that deliver clear benefits to patients relies on a strong R&D organisation.

As a biopharmaceutical leader, Cephalon has reinvested more than 18% of its sales revenue in R&D in 2008. This is one of the highest reinvestment rates in the biotech and pharmaceutical industries, the average rate being 15% in the other pharmaceutical companies. It is key to building a balanced pipeline of new chemical entities, new indications and product enhancements.

Paris, France
Pre-clinical Development Centre

• Support Drug Discovery by increasing the quality of compounds moving into clinical development
• Support Worldwide Development Programmes  
• Chemical Development Unit